Our Board of Trustees
NCRI is governed by a Board of Trustees. Their role is to set NCRI’s strategy (in consultation with NCRI Partners and other key stakeholders) and uphold our values and governance.
Baroness Delyth MorganBaroness Morgan is the Chief Executive of Breast Cancer Now and sits as a cross bench peer in the House of Lords. She spent 10 years at Breakthrough Breast Cancer, as the charity’s first Chief Executive, before which she worked at Shelter, Workplace Nurseries Campaign and Asthma UK. Delyth is a science graduate and Fellow of University College London. After becoming a life peer she was appointed to Government in 2007, when she served as Children’s Minister for the Department of Children Schools and Families, Minister for Intellectual Property and Quality at the Department of Innovation, Universities and Skills and Government spokesperson for the Department of Work and Pensions in the House of Lords.
Ms Mary BasterfieldMary is a qualified accountant, and is currently chief financial officer for the UK and Ireland at global media, digital marketing and communications group Dentsu Aegis Network. Her experience spans e-commerce, media, strategy, and financial management of businesses undergoing rapid change. Her previous roles include chief financial officer at Hotels.com and at Warner Music International. Mary is also currently a non executive director for the Royal Free London and a trustee of University College London Union, and she has previously served as a non-executive director and chair of audit committee for Hounslow and Richmond Community Healthcare NHS Trust.
Dr Helen CampbellHelen Campbell is Portfolio Manager for Department of Health Research Networks, Cancer Research, and Clinical Research Facilities. She is based at Exeter University Medical School and works full-time on behalf of the Department of Health. After obtaining a PhD in biochemistry, Helen worked in the medical device and pharmaceutical industry, before taking up post in 1994 as manager of the first NHS National Cancer R&D Programme. Since then, Helen has been involved in every major national development in cancer research in the NHS, including the establishment of the National Cancer Research Network and the National Cancer Research Institute.
Mr Alan ChantAlan Chant is a lay member on a number of cancer and research bodies, including Cancer Research UK, the MRC-hosted UK Clinical Research Collaboration Board, NIHR Programme Grants for Applied Research, UK Clinical Trials Gateway Project Board, Wellcome Trust Clinical Study Data Request panel and Oxford Biomedical Research Centre Patients Active in Research Group. He has also served on NICE cancer Guideline Development Groups. He is a Trustee of Oxford Radcliffe Hospitals Charitable Funds. He is also a myeloma cancer patient and has participated in a clinical trial. His business career was spent principally in marketing and business development roles in national and international consumer goods companies and he was a main Board Director in five companies. Academically his qualifications include a BA (Hons) in Business Studies, a post-graduate Diploma in Marketing and an MBA from Henley.
Mr Angus McNairAngus McNair is a NIHR Academic Clinical Lecturer in General Surgery at the University of Bristol and Specialist Registrar in colorectal surgery. He trained in Bristol and the south west of England and completed his doctorate in 2011. His research interests include doctor-patient communication in cancer care, patient and public involvement in research prioritisation and randomised trial methodology.
Dr Alasdair RankinAlasdair Rankin joined the blood cancer research charity Bloodwise as Director of Research in 2016. Previously he was Director of Research at Diabetes UK from 2012 to 2015 where he developed the organisations current research strategy, including leading the establishment of diabetes Clinical Studies Groups and broadening engagement of people living with diabetes in research. He began working for research funders at Cancer Research UK, where he held various roles including leading the research funding operations team and establishing and leading the research strategy team, contributing to the development and implementation of Cancer Research UK’s 2011-15 research strategy.
Ms Cathy ScivierCathy Scivier was a member of the leadership team at the Institute of Cancer Research (ICR), London for fourteen years, initially as HR Director and latterly as Chief Operating Officer, where a key part of the role was liaison with cancer research funding bodies. Cathy left the ICR in early 2016 to relocate to the north-west of England and now lives in Lancashire. From 2012-2016 she was the ICR’s nominated Governor on the Royal Marsden NHS Foundation Trust’s Governing Body. She has an MSc in HR Management and is a Fellow of the Chartered Institute of Personnel and Development. Prior to joining the ICR she spent over 20 years in healthcare management in the NHS in south west London. She is also a trustee of a number of other charities including the Syncona Foundation, a grant giving charity and n-Compass North West and advocacy and wellbeing charity. Cathy is also an Independent Member of the Audit Committee of the Greater Manchester Combined Authority.
Professor Charles SwantonCharles completed his MDPhD in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician scientist/medical oncology training in 2008. Charles combines his laboratory research at the Francis Crick Institute with clinical duties focussed on biological mechanisms of cancer drug resistance. Charles is the Chief Investigator of the CR-UK TRACERx lung cancer evolution study and co-directs the CRUK Lung Cancer Centre of Excellence. He was awarded the Royal College of Physicians Goulstonian lecture and Graham Bull Prize for Clinical Sciences in 2013 and appointed Fellow of the European Academy of Cancer Sciences in 2013 and Fellow of the Academy of Medical Sciences in 2015. Charles was awarded the Jeremy Jass Prize (2014), Stand up to Cancer Translational Cancer Research Prize (2015), Glaxo Smithkline Biochemical Society Prize in recognition of distinguished research leading to new advances in medical science and was awarded the Ellison-Cliffe Medal and Lecture, Royal Society of Medicine (2017) and the San Salvatore Prize for Cancer Research (2017). Charles was appointed Napier Professor in Cancer by the Royal Society in 2016.